In another study, Sen et al., by investigating the antitumor effects of EGCG in different tumor cell lines [MCF7 (breast cancer), A375 (melanoma) and HT-1080 (fibrosarcoma)], observed a dose-dependent decrease in MMP-2 mRNA levels and activity and also a greater difficulty of the cells in forming bonds with ECM components such as vibronectin and vitronectin [154]. This evidence concerns the gene MMP2 and breast cancer.